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Abstract 
We report a rare synchronous presentation
of adrenocortical carcinoma (ACC) and papil-
lary  thyroid  carcinoma  (PTC).  A  31-year-old
male first presented with a large left adrenal
mass that was identified during the workup for
refractory hypertension due to hyperaldostero-
nism. The mass was removed surgically with
pathology showing ACC. The patient was then
treated  with  adjuvant  radiation  therapy  and
mitotane  chemotherapy.  Four  months  post
ACC  resection,  metastatic  ACC  to  the  right
upper lung and PTC in the left lobe of the thy-
roid were found in surveillance imaging. He
subsequently developed pulmonary, contralat-
eral  adrenal  and  brain  metastases  from  his
ACC.  Li  Fraumeni  syndrome  and  Multiple
Endocrine Neoplasia Type I (MEN I) were con-
sidered,  but  testing  of  both  P53 and  menin
genes showed no mutation. We also performed
a review of the literature and found three sim-
ilar  cases,  however  gene  mutation  analysis
was not performed..
Introduction
In this report we review the case of a 31-
year-old male diagnosed with an adrenocorti-
cal carcinoma (ACC) and a papillary thyroid
carcinoma (PTC). Adrenocortical carcinomas
are an extremely rare type of cancer, with an
incidence of less than 0.2 per 100,000 in the
U.S.1 Thyroid cancer is more common with an
incidence rate of 11.0 per 100,000 per year in
the  U.S.;  papillary  carcinoma  accounts  for
approximately 85% of all thyroid cancers and is
3 times more common in women than men.2
Given the presentation of these rare tumors
together in a young patient, their appearance
is suggestive of a possible hereditary link. Of
the known syndromes caused by a hereditary
predisposition to multiple endocrine tumors,
none  specifically  include  the  occurrence  of
PTC with ACC.3 Of the hereditary conditions
that  present  with  the  tumors  in  our  case,
Multiple Endocrine Neoplasia (MEN) Type 1 is
known to present with more than 20 possible
combinations of endocrine and non-endocrine
tumors,  including  ACC  but  not  PTC.4 Addi  -
tionally,  MEN  Type  2  syndromes  involve
pheochromocytomas  and  medullary  thyroid
cancer, but do not traditionally involve PTC or
ACC  in  the  established  syndrome.3 Adreno-
cortical carcinomas are also known to appear
in Li-Fraumeni syndrome (LFS), which is asso-
ciated with an autosomal dominant mutation
in the TP53 gene that is the source of tumors
at an early age.5 There are few case reports in
the literature that present with ACC and PTC.
The  available  reports  attribute  the  concomi-
tant appearance of the tumors to coincidence,
but  do  not  discount  a  potential  genetic  or
hereditary link.6-8 Thus, this case represents
an atypical combination of endocrine tumors
with a potential hereditary component.
Case Report
A 31-year-old, previously healthy, white male
presented to the emergency department with a
nine-month  history  of  intermittent  fevers,
headaches and muscle aches occurring in iso-
lated episodes approximately a month apart, a
5-day  history  of  back  pain,  and  acute  onset
fevers  to  38.9°  Celsius.  Past  medical  history
included  gastroesophageal  reflux  disease
(GERD), controlled with lansoprazole. He was
taking no other medications prior to his initial
presentation. He was working as a construction
supervisor and had smoked half of a pack of cig-
arettes per day for the past 12 years. Significant
family history included a father with hyperten-
sion  and  congestive  heart  failure,  paternal
grandmother with leukemia, paternal aunt with
non-Hodgkin’s lymphoma, maternal uncle with
multiple myeloma, and a maternal great grand-
mother with metastatic colon cancer. A physical
exam revealed severe hypertension (210/110),
no palpable abdominal masses and was other-
wise unremarkable. He was prescribed atenolol
(50  mg  daily),  which  initially  controlled  the
high blood pressure.
However, the hypertension proved refractory
to treatment for four months, even while tak-
ing three anti-hypertensive drugs simultane-
ously (atenolol, valsartan and amlodipine). A
more  thorough  work-up  was  initiated.  An
abdominal  ultrasound  revealed  a  large  left
adrenal mass (Figure 1A). A follow-up CT scan
confirmed  a  14.5¥14.4¥9.8cm  left  adrenal
mass displacing the left superior pole of the
kidney. It was suspected that the severe hyper-
tension was secondary to a hormone-secreting
tumor, therefore cortisol and aldosterone lev-
els were checked prior to surgical resection of
the  mass.  Urine  metanephrine,  normeta  -
nephrine and serum levels were normal; aldos-
terone levels were slightly elevated, while the
aldosterone/renin activity ratio was above nor-
mal  limits  at  112.5  (ref.  ≤25.0),  indicating
hyperaldosteronism. 
Surgical resection of the adrenal mass was
performed;  pathology  revealed  a  19.5  cm
adrenocortical  carcinoma  with  large  vessel
invasion. The tumor was less than 1 mm from
the resection margin, but was surrounded by a
thin  fibrous  capsule  and  demonstrated  no
definitive  evidence  of  capsular  extension  or
invasion. The tumor was staged as pT2 with no
lymph nodes analyzed. The patient recovered
from  surgery  with  no  major  complications.
Post-operative CT scan revealed a left pleural
effusion, but was negative for metastatic dis-
ease.  Mild  hypertension  persisted,  managed
with 100 mg atenolol. Within two months fol-
lowing surgery, aldosterone levels returned to
normal. 
Six  weeks  following  the  operation,  the
patient began adjuvant radiation concurrent
with mitotane. He received a total dose of 54
Gy at 2 Gy/fraction given over 5.5 weeks to
the resection bed and preoperative tumor vol-
ume. Following completion of radiation, he
continued on single agent mitotane chemo-
therapy.
Four months following the original adrena-
lectomy, a surveillance CT scan revealed a 1 cm
nodule in the right upper lung. A subsequent
PETCT showed an FDG avid nodule (SUV 3.7)
in the right upper lung and a 4 mm FDG avid
left thyroid nodule (SUV 13.7) (Figure 1B, 1C).
The FDG avid lung nodule was thought to rep-
resent  metastatic  disease  (ACC  vs thyroid).
The  patient  underwent  thoracoscopic  right
upper and middle pulmonary lobe wedge resec-
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tions; pathology showed a 1.5 cm tumor consis-
tent  with  metastatic  ACC  with  a  negative
resection margin. Additionally, an ultrasound
guided fine needle aspiration (FNA) of the thy-
roid nodule was performed; pathology showed
PTC. Six months following the original adrena-
lectomy and 2 months following the thoraco-
scopic pulmonary wedge resection and thyroid
FNA, a short interval surveillance PETCT scan
showed no evidence of metastatic disease but
re-confirmed an FDG avid left thyroid nodule.
Given absence of further metastatic disease,
the patient underwent a total thyroidectomy;
pathology revealed multifocal PTC with posi-
tive margins. The patient was started on syn-
throid and I-131 radioactive iodine remnant
ablation was performed. The patient contin-
ued on single agent mitotane for a total of 8
months (6 weeks concurrent with radiation
and 6 months as a single agent). The maxi-
mum tolerated dose was 1500 mg daily; thera-
peutic  drug  levels  of  10-14  mg/L  were  not
reached due to GI side effects. The medica-
tion was stopped given rising creatinine and
concerns for renal toxicity.
Eleven  months  following  his  original
adrenalectomy and 7 months following the tho-
racoscopic  pulmonary  wedge  resection,  the
patient underwent a surveillance PETCT scan
which demonstrated a new 1 cm nodule in the
right upper lobe (SUV 5.2). The patient then
underwent  a  redo  thoracoscopic  right  upper
lobe  wedge  resection;  pathology  was  consis-
tent with fibrotic scar with no evidence of car-
cinoma. 
Eighteen  months  following  his  original
adrenalectomy  and  14  months  following  the
original  pulmonary  lobe  wedge  resection,
another surveillance PETCT scan demonstrat-
ed a new 4.5¥5.3¥4.7 cm right upper lobe mass
(SUV  8.3)  a  hypermetabolic  1.2  cm  pleural
based  mass,  and  a  hypermetabolic  nodular
right adrenal gland. He underwent a right tho-
racoscopic converted to open thoracotomy for
right  upper  lobectomy;  pathology  revealed
metastatic ACC 5 cm with negative margins, in
addition to a pleural-based metastasis. A post-
operative PETCT unfortunately showed rapid
disease  progression  in  the  right  hilum  and
right adrenal gland. The patient was started on
systemic  chemotherapy  with  5-fluorouracil
(5FU) and adriamycin. After one cycle of 5FU
and  adriamycin,  the  patient  developed  non-
focal neurologic changes. A brain MRI showed
multiple  right  parietal  small  lobulated
parenchymal  brain  enhancing  lesions  with
surrounding  vasogenic  edema  (Figure  1D);
there were additionally several small left tem-
poral occipital metastases. A craniotomy and
resection of parietal lesions were performed;
pathology  revealed  metastatic  adrenocortical
carcinoma.  He  subsequently  underwent
stereotactic radiosurgery to the resection bed.
The patient was then started on temozolomide
and capecitabine chemotherapy. In a matter of
weeks, the patient developed recurrent brain
metastases and additional metastases to bone
and multimple soft tissue sites. Despite whole
brain radiotherapy the patient had progessive
disease, a worsening performance status and
died, two years from his original diagnosis.
Genetic  testing  was  pursued  to  rule  out
known hereditary conditions that could poten-
tially cause the combination of ACC and PTC,
specifically  LFS  and  MEN  I.  Gene  mutation
analysis  revealed  a  wild-type  p53 gene.
Analysis of the menin gene also revealed no
mutation.  No  further  genetic  testing  was
obtained. Germline DNA was stored for future
research based whole genome sequencing.
Literature review
We performed a Medline search for cases
presenting with adrenocortical carcinomas or
adenomas  and  papillary  thyroid  carcinomas.
We  found  three  cases  that  matched  closely
with our patient (Table 1).
Fukushima  et  al.6 reported  a  45-year-old
female with a virilizing adrenocortical adeno-
ma,  a  papillary  thyroid  carcinoma,  and  a
benign pancreatic nodule. The authors consid-
ered the concomitant occurrence of multiple
endocrine lesions to be coincidental given the
lack of family history. However, the possibility
for MEN was considered, yet no genetic testing
was performed. Casula et al.7 reported the case
of a 39-year-old male who was found to have a
Case Report
Table 1. Literature review of case reports containing papillary thyroid carcinoma and
adrenal lesions.
Author Age Sex Adrenal Thyroid Other  Symptoms Recurrence
pathology pathology tumors
Fukushima6 45 F Adenoma PTC Pancreas  Cushing’s No
nodule syndrome
Casula7 39 M Adenoma PTC None Elevated No
aldosterone
Noordzig8 64 F Carcinoma PTC Liver None No
metastases
from ACC
Figure 1. A) Left adrenal mass, MRI; B) Right upper lobe pulmonary nodule, PETCT
Scan; C) Thyroid nodule, PETCT Scan; D) R parietal brain metastases and associated
edema, MRI with contrast.
AB
CD[Rare Tumors 2011; 3:e45] [page 143]
locally  advanced  papillary  thyroid  carcinoma
and  an  aldosterone-secreting  adrenocortical
adenoma. Again, the association of the tumors
was ruled to be most likely coincidental, how-
ever  MEN  was  considered  despite  no  family
history  or  genetic  testing.  Noordzig,  et  al.8
described four cases where a thyroid neoplasm
was discovered by PETCT in the course of care
for another primary lesion. One case was that
of a 64-year-old woman initially found to have
an adrenocortical carcinoma, who also had a
papillary  thyroid  carcinoma  discovered  by
PETCT  imaging  and  biopsy.  Again,  genetic
testing was not performed.
Discussion
In summary, we reported the case of a 31-
year-old  male  who  initially  presented  with
severe hypertension and was found to have an
aldosterone-secreting metastatic adrenocorti-
cal carcinoma. After resection of the ACC, the
patient was found to have a localized PTC and
subsequently developed metastatic ACC to the
lungs and brain. Of primary concern for this
case  was  the  appearance  of  two  endocrine
tumors within a short period of time and the
possibility of an underlying hereditary cancer
syndrome. Both tumors are relatively rare in
the general population, and their appearance
together  seemed  suggestive  of  a  hereditary
component, however tests for LFS and MEN I
both returned negative.
Adrenocortical carcinomas are rare and typ-
ically have a poor prognosis. There are varying
reports  on  the  percentage  of  ACCs  that  are
functioning, with some papers indicating as
many as 79% of ACCs as functioning – produc-
ing one or more adrenal hormones.9Most func-
tioning  ACCs  produce  glucocorticoids.  ACC
often  presents  with  hypertension;  primary
hyperaldosteronism is less common. The most
effective treatment for ACC is complete resec-
tion ,10 which was performed in the case of our
patient.  In  cases  of  incomplete  resection  or
non-operated  tumors,  survival  is  often  less
than  one  year.11-13 Survival  varies  based  on
extent of disease, with Stage IV disease show-
ing a five-year survival of 22%.12
Studies  of  adjuvant  treatment  following
resection of ACCs demonstrate mixed results.
A retrospective study by Terzolo et al. included
56  centers  and  177  patients  with  ACC  in
Germany  and  Italy  showed  recurrence  free-
survival  was  extended  to  42  months  in  the
group receiving adjuvant mitotane chemother-
apy as opposed to 10 months in the control
groups.14 Other retrospective studies of adju-
vant mitotane therapy have shown no advan-
tage over surgical resection alone.15,16 However,
these studies were primarily conducted at sin-
gle  centers  and  did  not  contain  as  many
patients compared to the Terzolo study. There
is an ongoing prospective phase III study (ADI-
UVO study) of patients with ACC comparing
adjuvant mitotane vs. follow-up that will hope-
fully  offer  greater  clarity  on  the  benefits  of
adjuvant mitotane therapy (NCT00777244).
The  role  of  adjuvant  radiation  is  also  ill-
defined, but studies have suggested that the
risk of local recurrence, particularly with larg-
er tumors, can be quite high. In a matched-pair
analysis by Fassnacht et al., the investigators
reported a 79% local control in 14 patients who
received adjuvant radiotherapy compared with
12% (P<0.01) in 14 patients matched for stage,
resection status, the use of adjuvant mitotane,
and tumor size.17 Sabolch et al. demonstrated
4.7 times risk of local failure (P=0.03) in 58
patients treated for primary disease and recur-
rent  disease  who  did  not  receive  adjuvant
radiotherapy.18 Recommendations  have  been
proposed by the investigators from University
Hospital Wuerzberg are for adjuvant radiation
for tumors ≥8 cm or for tumors with question-
able margin status.19 A minimum dose of 40 Gy
should be given and doses between 50-60 Gy
should be considered using standard fraction-
ation. Radiotherapy was given in this patient
due to the large size of the tumor and the very
close margin.
Papillary thyroid carcinomas are much less
aggressive than ACC and therefore have a bet-
ter  prognosis  post-resection.  The  primary
treatment for PTC is surgical resection. Since
our patient had multifocal disease, a total thy-
roidectomy  was  performed  to  reduce  risk  of
recurrence. About 15% of patients with PTC
will  experience  relapse  following  surgical
resection of the thyroid and approximately 5%
of  all  PTC  cases  are  lethal.20 Cause  specific
survival  for  patients  undergoing  total  thy-
roidectomy is reported at 100% in some studies
for  patients  with  less  advanced  disease.21
However,  the  combined  presentation  of  PTC
and  ACC  complicates  the  prognosis  for  our
patient.
Most ACCs and PTCs are sporadic, however,
given  the  occurrence  of  two  different  endo  -
crine neoplasms within a short period of time
and the young age of our patient, the possibil-
ity of a hereditary cancer syndrome was con-
sidered. The most likely hereditary syndromes
for this case associated with ACC were MEN
(mutation in menin), and LFS (mutation in
the  TP53).  While  no  hereditary  cancer  syn-
dromes were identified in this case, this does
not preclude the possibility of an untested or
unknown disorder. 
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Abstract 
Interdigitating  Dendritic  Cell  Sarcoma
(IDCS) is an infrequent dendritic cell tumor
which  mainly  affects  the  lymphatic  system.
Intestinal  metastasis  from  uterine  IDCS  is
extremely rare. Here we report a case of a 76-
year-old female presenting with vaginal bleed-
ing and acute abdomen. The final diagnosis
revealed  a  small  bowel  perforation  due  to
metastatic  involvement  from  uterine  cervix
IDCS. In this paper, we report the clinical man-
ifestation,  computed  tomography  and
histopathological findings helpful for the accu-
rate diagnosis of this rare tumor. 
Introduction
Interdigitating  Dendritic  Cell  Sarcoma
(IDCS)  is  an  extremely  rare  neoplasm.
According  to  the  World  Health  Organization
(WHO) dendritic cell neoplasms are classified
into five groups: Langerhans Cell Histiocytosis
(LCH),  Langerhans  Cell  Sarcoma  (LCS),
Interdigitating  Dendritic  cell  Sarcoma/Tumor
(IDCS/T),  Follicular  Dendritic  Cell
Sarcoma/Tumor (FDCS/T), and Dendritic Cell
Sarcoma.1 Dendritic cells are antigen-present-
ing cells and play crucial role in the immune
system, especially in generating and regulat-
ing  the  germinal  cell  reaction.  The  subtype
Interdigitating Dendritic Cells stimulate T lym-
phocytes and are found in the T cell areas of
the lymphoid tissue. IDCS mainly occurs in the
lymph  nodes;  however  extranodal  involve-
ments such as nasopharynx, skin, testis, ovary,
urinary bladder, tonsils, small intestine, and
pleura have been previously described.2 Here
we  report  an  uncommon  case  of  extranodal
IDCS  primarily  affecting  the  uterine  cervix,
associated with metastatic involvement of the
small intestine which presented with vaginal
bleeding and acute abdomen due to bowel per-
foration.
Case Report
A 76-year-old female presented to our emer-
gency room with vaginal bleeding, epigastric
abdominal pain and constipation. The vaginal
bleeding appeared 3 weeks before the admis-
sion. Medical history was significant for essen-
tial hypertension, diabetes mellitus controlled
with oral drugs, cerebrovascular accident and
cholecystectomy. Family history was negative
for  malignancy.  At  presentation,  the  patient
had unremarkable vital signs. Her laboratory
tests were normal except for anemia with 10.8
g/dL  hemoglobin.  Her  physical  examination
revealed a soft, non-tender abdomen without a
palpable  abdominal  mass.  A  small  umbilical
hernia without incarcerated content was also
detected. There was no evidence of masses,
fecal impaction, blood or melena at the digital
rectal examination. Gynecologic examination
detected  an  irregular  mass  originating  from
the uterine cervix and obliterating the upper
vagina. The patient was admitted to the gyne-
cology department for further evaluation. 
For  anatomical  information  and  staging,
thoracic,  abdominal  and  pelvic  CT  scan  was
performed. The CT scan of thorax was normal.
Abdominal CT revealed a 25×20 mm homoge-
neous soft tissue mass in close proximity to a
small bowel loop (jejunum) (Figure 1). In addi-
tion, a large heterogeneous solid mass in the
uterine cervix and vagina was noted (Figure
2). There was no evidence of ascites, intraperi-
toneal dissemination or lymphadenopathy. 
During the hospitalization the patient under
went a colposcopy and multiple biopsies were
taken from the distal cervix and proximal vagi-
na,  area  involved  with  the  mass.  Neoplastic
markers including: AFP-B, CEA-B, CA 153-B,
CA 125-B and CA19.9 were within the normal
limits. While waiting for the pathologic results,
she was discharged with follow-up in the out-
patient clinic. Four days later, and before get-
ting the pathologic results the patient again
presented in the emergency room with acute
severe generalized abdominal pain, that was
more  prominent  in  the  center  and  upper
abdomen.  She  had  fever,  tachycardia  (105
beats per minute) and normal blood pressure.
Her abdominal examination revealed general-
ized  tenderness,  rigidity,  guarding  and
rebound. Her laboratory tests were within the
normal limits except for leukocytosis and neu-
trophilia.  After  adequate  fluid  resuscitation
she was taken to the operation room for explo-
rative laparotomy. The operation findings were
pus in the peritoneal cavity, perforated small
intestine neoplastic mass about 70 cm distally
to  the  Treitz  ligament,  small  uterine,  tumor
involving the cervix without any dissemination
to the abdominal cavity. She underwent small
bowel resection with about 10 cm macroscopic
free  margins,  and  hand-sewing  double  layer
anastomosis  was  preformed.  After  adequate
irrigation of the peritoneal cavity the abdomen
closed  by  anatomical  layers.  Pathological
examination showed homogeneous white tis-
sue that infiltrates the bowel wall and forms
two  nodular  masses  within  the  mesentery.
Microscopic examination showed a poorly dif-
ferentiated malignant neoplasm with variably
epithelioid or spindle cytomorphology (Figure
3). The tumor cells have elongated tapering or
else plump vesicular nuclei and indistinct pale-
ly eosinophilic cytoplasm. The biopsy from the
region of the cervix is substantially more pleo-
morphic than the one in the small bowel and
there  is  extensive  necrosis.  Immunostains
performed  on  the  small  bowel  mass  showed
focally  strong  positivity  for  keratin  CAM  5.2
and also pan-keratin, while CD34, SMA, LCA,
CD45Ro, CD163 MART-1 and desmin are nega-
tive with only some weak focal and likely non-
specific positivity for MITF. Furthermore, the
S-100 stain highlights the fact that many of the
neoplastic cells have elongated dendritic cyto-
plasmic  processes  (an  appearance  which
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